Immunohistologic Features of Cerebral Venous Thrombosis Due to Vaccine-Induced Immune Thrombotic Thrombocytopenia
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received January 13, 2023
- Accepted in final form April 5, 2023
- First Published May 26, 2023.
Author Disclosures
- Thomas Geeraerts, MD, PhD,
- Céline Guilbeau-Frugier, MD, PhD,
- Cédric Garcia, MSc,
- Vincent Memier, MD, PhD,
- Nicolas Raposo, MD, PhD,
- Fabrice Bonneville, MD, PhD,
- Céline Gales, MD, PhD,
- Jean Darcourt, MD, PhD,
- Sophie Voisin, MD, PhD,
- Agnès Ribes, MD, PhD,
- Marie Piel-Julian, MD,
- Fanny Bounes, MD, PhD,
- Jean François Albucher, MD,
- Franck-Emmanuel Roux, MD, PhD,
- Jacques Izopet, MD, PhD,
- Norbert Telmon, MD, PhD,
- Jean Marc Olivot, MD, PhD,
- Pierre Sié, MD, PhD,
- Jan Bauer, PhD,
- Bernard Payrastre, PhD* and
- Roland S. Liblau, MD, PhD*
- Thomas Geeraerts, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Céline Guilbeau-Frugier, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Cédric Garcia, MSc,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Vincent Memier, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Nicolas Raposo, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Fulbright, (2) Arthur Sachs, (3) Philippe foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Fabrice Bonneville, MD, PhD,
None
NONE
None
1) Neuroradiology, Editorial board since 2015
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Céline Gales, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Jean Darcourt, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Sophie Voisin, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Agnès Ribes, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Marie Piel-Julian, MD,
None
NONE
(1)Novonordisk(2) CSL behring(3) Amgen(4) Sobi(5) Bayer
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Fanny Bounes, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Jean François Albucher, MD,
None
NONE
fees from Bayer and Pfizer for scientific speechs
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Franck-Emmanuel Roux, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Jacques Izopet, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Norbert Telmon, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Jean Marc Olivot, MD, PhD,
DIRECT ANGIO study
NONE
Bristol Myers SquibbBoehringer
StrokeSection Editor 2015-2019StrokeAssistant Editor 2020-JAHA Guest Editor 2023-Frontiers of Neurology-StrokeAssociate Editor 2018
NONE
NONE
NONE
BoehringerAbbvie
NONE
NONE
NONE
NONE
French department of Health 2022
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Pierre Sié, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Jan Bauer, PhD,
None
NONE
None
Acta Neuropathologica Communications, Editor, 3 years.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
FWF Austrian Science Fund: P 34864-B. Second of 4 years.
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Bernard Payrastre, PhD* and
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Roland S. Liblau, MD, PhD*
(1) Biogen(2) Novartis
NONE
(1) Merck: funding for travel to Congress
(1) Frontiers in Neurology(2) Journal of Molecular Medicine(3) OncoImmunology(4) BRAIN Editorial Advisory Board 2015-2020
NONE
NONE
NONE
(1) Biogen: consulting and educational efforts(2) Novartis: consulting and educational efforts(3) Merck: consulting and educational efforts
NONE
(1) Board member of the International Society for NeuroImmunology (ISNI);(2) Scientific board member of the French MS society (ARSEP); (3) Member of the EAN Panel on Neuroimmunology
NONE
(1) Grant for research from Roche(2) Grant for research from GSK(3) Grant for research from BMS
(1) Agence Nationale pour la Recherche CE17-0014 (2) BETPSY RHU 18- RHUS-0012
(1) European Union: ERA-Net NARCOMICS
(1) Fondation pour la Recherche Médicale;(2) ARSEP-French MS Society
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France.
- Correspondence
Dr. Liblau roland.liblau{at}inserm.fr
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.